Novo Nordisk Settles Over US Federal Investigation Of Marketing Practices
Executive Summary
Novo Nordisk has settled with the US Federal government over claims it did not comply with communicating safety information on its diabetes drug Victoza.
You may also be interested in...
The Benefits Of A Corporate Integrity Agreement: An Industry Perspective
Novo exec says CIAs can help spur culture change to improve sales rep compliance; cooperation can also help avoid corporate integrity agreements in future settlements.
Refocused Novo Nordisk Says On 'Road To Recovery' After Traumatic 2016
Novo Nordisk's head of international operations says the company has learned from the past, taken corrective steps, and is now on the road to recovery.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.